We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
Read MoreHide Full Article
Key Takeaways
ABBV's neuroscience revenues rose 21.8% to $6.1 billion in the first half of 2026.
Vraylar, Botox Therapeutic, Ubrelvy and Qulipta delivered double-digit sales growth in the period.
Vyalev is driving PD growth, while tavapadon could add another franchise pillar if approved.
AbbVie (ABBV - Free Report) has significantly transformed its neuroscience portfolio over the years, evolving it from a relatively concentrated business initially anchored by Vraylar and Botox Therapeutics into a broader, multi-franchise platform.
The company has expanded into migraine with Ubrelvy and Qulipta and established a Parkinson’s disease (PD) franchise with Vyalev, broadening its neuroscience presence beyond its traditional psychiatry and neurotoxin therapies. This expansion has not only diversified AbbVie’s revenue base but also created multiple avenues for sustained growth.
AbbVie’s Neuroscience Growth Remains Broad-Based
The transformation is increasingly visible in the franchise’s financial performance. AbbVie’s neuroscience portfolio generated $6.1 billion in revenues in the first half of 2026, up 21.8% year over year on an operational basis, making it one of the company’s fastest-growing therapeutic areas. Importantly, growth was broad-based across its three key pillars — psychiatry, migraine and PD — rather than being driven by a single product.
Vraylar remains the cornerstone of AbbVie’s psychiatry franchise. The drug generated $1.98 billion in revenues in the first half of 2026, up 18.6% year over year, with AbbVie citing continued share gains in bipolar disorder and adjunctive major depressive disorder.
Migraine has emerged as a major pillar of AbbVie’s neuroscience portfolio. Alongside Botox Therapeutic, the company now markets the oral CGRPs Ubrelvy and Qulipta, creating a portfolio spanning both preventive and acute migraine treatment. In the first half of 2026, Botox Therapeutic generated $2.05 billion, while Ubrelvy and Qulipta generated $731 million and $646 million, respectively. Sales of all three products increased at double-digit rates from the year-ago period, with Qulipta leading growth at 39.2%, followed by Ubrelvy at 26.4%.
PD represents the newest pillar of AbbVie’s neuroscience franchise, with Vyalev emerging as a significant growth driver. The therapy generated $457 million in first-half 2026 sales, up sharply from the prior-year period, while second-quarter sales increased more than 27% sequentially. AbbVie said Vyalev is well on track to achieve blockbuster sales this year.
The strong performance has prompted AbbVie to raise its full-year outlook for the franchise. The company now expects 2026 neuroscience revenues of approximately $12.7 billion, $100 million above its previous forecast, including Vraylar sales approaching $4.1 billion and Botox Therapeutic sales expected to reach nearly $4.2 billion. AbbVie also raised its overall 2026 revenue outlook by $300 million to approximately $67.6 billion.
A Potential FDA Nod Could Add Another Growth Driver for ABBV
Beyond the continued uptake of its marketed therapies, AbbVie could add another growth driver to its neuroscience portfolio with tavapadon, a once-daily oral therapy for PD. The drug is a selective D1/D5 dopamine agonist being developed as both a monotherapy and an add-on to standard of care, giving the company another mechanism to address PD.
AbbVie expects an FDA decision on tavapadon in the third quarter of 2026. If approved, the drug could launch later this year, expanding the company’s PD portfolio alongside Vyalev and Duopa. Management expects the three therapies to collectively represent a PD opportunity of more than $5 billion in peak sales.
AbbVie is also advancing a pipeline of neuroscience programs across several areas. It recently initiated a phase II study on GemibotulinumtoxinA, a next-generation toxin for essential tremor, and a phase Ib study of ABBV-1758, an amyloid-beta antibody for the treatment of Alzheimer’s disease. These programs broaden AbbVie’s neuroscience ambitions beyond its established products, providing additional opportunities to replenish and diversify the portfolio over the longer term.
ABBV’s Competition in the Neuroscience Space
Other bigger players in the neuroscience space are Biogen (BIIB - Free Report) and Johnson & Johnson (JNJ - Free Report) .
As revenues from its legacy multiple sclerosis portfolio continue to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for AD. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression.
J&J's neuroscience business is anchored by the depression therapy Spravato and the long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year further strengthened its portfolio by adding Caplyta, an approved treatment for schizophrenia and bipolar depression.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year-to-date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.93 times forward earnings, lower than its industry’s average of 18.07.
Image Source: Zacks Investment Research
ABBV’s EPS estimates for 2026 and 2027 have declined over the past 30 days.
View the Zacks #1 Rank List
Image: Shutterstock
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
Key Takeaways
AbbVie (ABBV - Free Report) has significantly transformed its neuroscience portfolio over the years, evolving it from a relatively concentrated business initially anchored by Vraylar and Botox Therapeutics into a broader, multi-franchise platform.
The company has expanded into migraine with Ubrelvy and Qulipta and established a Parkinson’s disease (PD) franchise with Vyalev, broadening its neuroscience presence beyond its traditional psychiatry and neurotoxin therapies. This expansion has not only diversified AbbVie’s revenue base but also created multiple avenues for sustained growth.
AbbVie’s Neuroscience Growth Remains Broad-Based
The transformation is increasingly visible in the franchise’s financial performance. AbbVie’s neuroscience portfolio generated $6.1 billion in revenues in the first half of 2026, up 21.8% year over year on an operational basis, making it one of the company’s fastest-growing therapeutic areas. Importantly, growth was broad-based across its three key pillars — psychiatry, migraine and PD — rather than being driven by a single product.
Vraylar remains the cornerstone of AbbVie’s psychiatry franchise. The drug generated $1.98 billion in revenues in the first half of 2026, up 18.6% year over year, with AbbVie citing continued share gains in bipolar disorder and adjunctive major depressive disorder.
Migraine has emerged as a major pillar of AbbVie’s neuroscience portfolio. Alongside Botox Therapeutic, the company now markets the oral CGRPs Ubrelvy and Qulipta, creating a portfolio spanning both preventive and acute migraine treatment. In the first half of 2026, Botox Therapeutic generated $2.05 billion, while Ubrelvy and Qulipta generated $731 million and $646 million, respectively. Sales of all three products increased at double-digit rates from the year-ago period, with Qulipta leading growth at 39.2%, followed by Ubrelvy at 26.4%.
PD represents the newest pillar of AbbVie’s neuroscience franchise, with Vyalev emerging as a significant growth driver. The therapy generated $457 million in first-half 2026 sales, up sharply from the prior-year period, while second-quarter sales increased more than 27% sequentially. AbbVie said Vyalev is well on track to achieve blockbuster sales this year.
The strong performance has prompted AbbVie to raise its full-year outlook for the franchise. The company now expects 2026 neuroscience revenues of approximately $12.7 billion, $100 million above its previous forecast, including Vraylar sales approaching $4.1 billion and Botox Therapeutic sales expected to reach nearly $4.2 billion. AbbVie also raised its overall 2026 revenue outlook by $300 million to approximately $67.6 billion.
A Potential FDA Nod Could Add Another Growth Driver for ABBV
Beyond the continued uptake of its marketed therapies, AbbVie could add another growth driver to its neuroscience portfolio with tavapadon, a once-daily oral therapy for PD. The drug is a selective D1/D5 dopamine agonist being developed as both a monotherapy and an add-on to standard of care, giving the company another mechanism to address PD.
AbbVie expects an FDA decision on tavapadon in the third quarter of 2026. If approved, the drug could launch later this year, expanding the company’s PD portfolio alongside Vyalev and Duopa. Management expects the three therapies to collectively represent a PD opportunity of more than $5 billion in peak sales.
AbbVie is also advancing a pipeline of neuroscience programs across several areas. It recently initiated a phase II study on GemibotulinumtoxinA, a next-generation toxin for essential tremor, and a phase Ib study of ABBV-1758, an amyloid-beta antibody for the treatment of Alzheimer’s disease. These programs broaden AbbVie’s neuroscience ambitions beyond its established products, providing additional opportunities to replenish and diversify the portfolio over the longer term.
ABBV’s Competition in the Neuroscience Space
Other bigger players in the neuroscience space are Biogen (BIIB - Free Report) and Johnson & Johnson (JNJ - Free Report) .
As revenues from its legacy multiple sclerosis portfolio continue to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for AD. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression.
J&J's neuroscience business is anchored by the depression therapy Spravato and the long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year further strengthened its portfolio by adding Caplyta, an approved treatment for schizophrenia and bipolar depression.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year-to-date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.93 times forward earnings, lower than its industry’s average of 18.07.
Image Source: Zacks Investment Research
ABBV’s EPS estimates for 2026 and 2027 have declined over the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.